Does 81383 require prior authorization?

No, 81383 does not require prior authorization (high confidence). Code is covered without prior authorization.

What is the Medicare reimbursement rate for 81383?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

HCPCS/CPT

No Prior Auth Required

Code is covered without prior authorization (high confidence)

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

The article does not specify documentation requirements; follow the documentation, medical record, and prior authorization requirements described in LCD MolDX: Repeat Germline Testing L38429 and MolDX program guidance.
Required documentation, coding guidance, and claim submission instructions are those stated in LCD L37003; this billing/coding article defers to that LCD for specific documentation and form requirements.
For Part A UB04 paper claim forms, enter the DEX Z-Code adjacent to the CPT code in Block 80.
For Part B electronic 5010A1 837P claims, enter the DEX Z-Code adjacent to the CPT code in Loop 2400 or SV101-7.

Coverage for repeat germline testing is determined by the referenced Local Coverage Determination MolDX: Repeat Germline Testing L38429; consult that LCD for specific clinical indications that constitute covered testing.
Coverage indications for HLA-DQB1*06:02 testing are specified in the associated LCD L37003 and must be followed for claims under this billing/coding article.
To report a Molecular Diagnostic Test (MDT) service, submit the appropriate CPT code, include the appropriate DEX Z-Code identifier adjacent to the CPT code in the claim comment/narrative field, and enter 1 unit of service (UOS).
Pharmacogenomics (PGx) testing is covered when ordered to guide selection or dosing of specific drug(s) that the ordering physician is considering for the beneficiary and when the test is likely to identify the necessary alleles/variants to inform therapy.
PGx testing is covered for the gene–drug pairs listed in the policy Tables 1 and 2 when the specific listed drug(s) are under consideration and the test result would inform clinical management (examples include CYP2C19 testing for clopidogrel and CYP2D6 testing for codeine/tramadol).
Testing of CYP2C9 and VKORC1 for warfarin dosing is covered only in accordance with NCD 90.1 and the requirements set forth in that NCD.

L38429 — MolDX: Repeat Germline Testing

J05

L38435 — MolDX: Pharmacogenomics Testing

J05

A57575 — Billing and Coding: MolDX: HLA-DQB1*06:02 Testing for Narcolepsy

J05

A57100 — Billing and Coding: MolDX: Repeat Germline Testing

J05

L37003 — MolDX: HLA-DQB1*06:02 Testing for Narcolepsy

Ask Verity about documentation requirements, denial risks, or coverage in your state.